Apolipoprotein A-II, HDL metabolism and atherosclerosis.
about
Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseReduced apolipoprotein glycosylation in patients with the metabolic syndromec-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.The effect of weight loss on HDL subfractions and LCAT activity in two genotypes of APOA-II -265T>C polymorphismGenetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Kinetic stabilization and fusion of apolipoprotein A-2:DMPC disks: comparison with apoA-1 and apoC-1.Role of the tumor suppressor IQGAP2 in metabolic homeostasis: Possible link between diabetes and cancer.Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein.Expression and purification of recombinant human apolipoprotein A-II in Pichia pastoris.Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approachAlterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein BApolipoprotein A-II-mediated conformational changes of apolipoprotein A-I in discoidal high density lipoproteins.Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease.Identification of Sequence Variation in the Apolipoprotein A2 Gene and Their Relationship with Serum High-Density Lipoprotein Cholesterol Levels.High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coliThe structure of apolipoprotein A-I in high density lipoproteins.Differential stability of high-density lipoprotein subclasses: effects of particle size and protein composition.Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.Heritability of serum apolipoprotein concentrations in middle-aged Japanese twins.Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL.Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development.The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I.Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.Proteomic and lipid characterization of apolipoprotein B-free luminal lipid droplets from mouse liver microsomes: implications for very low density lipoprotein assembly.Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease.Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer.Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down/bottom-up integrated approaches.Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II.High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.Advances in quantifying apolipoproteins using LC-MS/MS technology: implications for the clinic.MicroRNA-7 mediates cross-talk between metabolic signaling pathways in the liver.HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress.Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II with high on-treatment platelet reactivity in patients with ST-segment elevation myocardial infarction.Are dietary preferences linked to genes?
P2860
Q28075372-0AE48967-5F6B-47D8-AC00-D65F72EF4424Q28541818-CBCF0549-B71C-4034-ADC4-CDCEF5D52ED3Q30493483-E8134FA1-3700-4504-BA1D-0792C9D4D6DBQ33730096-7CACBF2B-BFCD-476D-8C34-E7A1009D05D4Q33759643-7C88D0D4-04F0-4754-B022-B337932332C1Q34061748-14C62223-7029-443D-8153-CF94D50DA4FFQ34189856-4EC4D1AA-885C-4FDD-9526-1C65CF8E4342Q34218516-D0CB5501-2DCF-42BA-9471-CDDED833EFB9Q34314185-93DBDA5F-C150-480F-8FE7-75A7CD603813Q35015334-31FD1444-BEC5-4CE2-AAAB-1BE7B0EAA482Q35104849-338E04F6-6271-413F-91F2-E466B1B969BFQ35592465-7F97C387-D5B7-45FE-B664-8B31F0828E24Q35640331-C462A703-09CD-4CC1-A8C5-AD81C9798680Q35754375-7AE84058-20AD-4ABD-A3E0-6D3FB9922949Q35770053-21358FED-1B07-4BE4-8AA7-57FDF5701A53Q35802050-9E06E2AC-F6BD-46C7-915D-F48FC2A94F43Q36007212-DC008391-9E08-4541-B97E-EE4CAD829790Q36037988-956A01D5-B733-421C-9112-8B9A7541C0BDQ36502193-410CF162-2577-4F64-86C4-540DD8081DF0Q36520394-1F2288C7-68F8-4375-BD15-E2BFCABADCCCQ36831855-5B427E8F-E7FD-4BAE-936E-153681497EB6Q37252779-E90B17EA-FD94-4BB7-847E-BB2E2513D351Q37334578-33975ADA-3691-4A01-91C3-1BE7C68EBC82Q37583257-5A357D22-1FDE-4232-AEF8-23F9DC6EEA4AQ38013180-89576909-BB84-46CB-AAD5-91E146703DDBQ38089207-9C9EFD99-71A8-48D7-AF33-CE3297286649Q38194113-8ADF8333-6A13-4697-9CFC-F62046D8034CQ39262850-81A6D205-4B29-4F6F-9CB4-FBEAB9D04C5FQ40082416-726AC47F-43A8-423A-9750-370A97694C3CQ42339302-DE194C1A-BDDB-49C3-B9A2-E025FD427A56Q43864805-79E7BA7D-EFCF-49D8-88DC-E37E2DBD83A1Q44190698-572752B9-B09E-4169-A212-3BD19AC4228FQ44516309-48BB80C4-79C6-4517-AD04-543BF0298B1BQ45091537-70CAF141-FFEF-45BE-9B27-558129C580BAQ45870343-0E0DC18F-705F-4AC5-BF3C-B76974C74F3EQ47859533-EF6C502B-B542-4A46-A9F2-9F14CAD3C641Q48267205-7338FD2A-59A2-45E9-B21E-1097C2C3208DQ51790864-F2F8BCE8-F5C6-48B4-ACD9-190753033AA7Q55258177-9E4A8D2D-E316-43F3-807B-B6F862637245Q57336943-75255ED4-729F-4C83-84F9-B94B57286719
P2860
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@ast
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@en
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@nl
type
label
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@ast
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@en
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@nl
prefLabel
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@ast
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@en
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@nl
P1433
P1476
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
@en
P2093
Patrick Duriez
Véronique Clavey
P356
10.1016/S0021-9150(01)00751-1
P577
2002-09-01T00:00:00Z